Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 12, 2025 22:28 ET | Source: Compass Therapeutics

Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering

BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based...
August 11, 2025 07:00 ET | Source: Compass Therapeutics

Compass Therapeutics Reports 2025 Second Quarter Financial Results and Provides Corporate Update

In the ongoing Phase 2/3 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer, fewer deaths have been observed than originally projected. We believe...
November 12, 2024 08:00 ET | Source: Compass Therapeutics

Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate Update

Fully enrolled the Phase 2/3 trial of lead asset CTX-009 (DLL4 and VEGF-A bispecific antibody) in patients with biliary tract cancers (BTC); top-line data readout is on track for the end of the first...
August 12, 2024 08:00 ET | Source: Compass Therapeutics

Compass Therapeutics Reports 2024 Second Quarter Financial Results and Provides Corporate Update

Compass Therapeutics announces 2nd quarter results and provides clinical results update
May 13, 2024 08:00 ET | Source: Compass Therapeutics

Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update

Received FDA Fast Track Designation for the investigation of CTX-009 in combination with paclitaxel for the treatment of patients with metastatic or locally advanced biliary tract tumors. Enrollment...
May 09, 2022 08:00 ET | Source: Compass Therapeutics

Compass Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress

The FDA cleared the investigational new drug application for CTX-009 (DLL4 X VEGF-A bispecific) in January allowing the Company to expand the ongoing Phase 2 study in patients with biliary tract...